Trendlines Q3 2017 Financial Report: 12.4% rise in Portfolio Value to US$94 million compared to 31.12.16

Company Reports US$3.0 million Q3 2017 Net Profit

Misgav, Israel and Singapore, 9 November 2017 – The Trendlines Group Ltd. (the "**Company**" and together with its subsidiaries and associated companies, **"Trendlines"** or the "**Group**") an Israeli company developing innovation-based companies in the medical and agricultural fields, announced its financial results for the three months ended 30 September 2017 ("**Q3 2017**").

Group Financial Highlights

Q3 2017

- US$5.3 million gain in the fair value of investments in portfolio companies during Q3 2017, compared to a gain of US$0.6 million in Q3 2016.
- US$6.8 million Q3 2017 total income, compared to US$4.1 million in Q3 2016.
- US$3.0 million Q3 2017 net profit, compared to $1.6 million in Q3 2016.
- Portfolio fair value of US$94.0 million at 30 September 2017, a 12.4% rise compared to US$83.7 million at 31 December 2016.
- Total current assets of US$12.4 million at 30 September 2017, compared to US$17.3 million at 31 December 2016.

Corporate/Business Developments

Q3 2017

- Trendlines and Shoushan Wealth Holdings established a joint venture in China to help Trendlines' portfolio companies and other Israeli and Asian companies penetrate the medical market in China.
- A strategic partnership was established with Chinese multinational, Haier Hai Chuanghui Incubator and Ventures ("**Haier HCH**").
- Two new portfolio companies were established in Israel: - BiPS Medical Ltd., and FruitSpec Ltd.
- Trendlines Medical Singapore announced its first portfolio investment, in InterVaal Pte. Ltd
- Five portfolio companies raised a total of US$7.6 million during the third quarter, three of which included the participation of strategic investors.
- Two exit-related events were announced: (1) the first stage in a 2-stage agreement for the sale of Trendlines' holding of MitrAssist Ltd; and (2) an investment in Vensica Medical Ltd. by Cogentix Medical, Inc. ("**Cogentix**") of US$2 million with an option for Cogentix to acquire the entire share capital of Vensica.

Post-Q3 Developments

- Trendlines raised gross proceeds of S$14.03 million (approximately US$10.3 million) through a placement of 100 million new shares. The placement subscribers included cornerstone investor B. Braun Melsungen AG and prominent Singapore-based institutional and corporate investors.
- Trendlines completed a strategic review and announced cost cutting objectives and targets
- Trendlines announced its dividend policy for FY2018 and FY2019

2017 Third Quarter Financial Results

"We are pleased to report a second consecutive quarter of net profit which again reflects strong gains in the fair value of investments in our portfolio companies," said Todd Dollinger, Chairman and CEO of Trendlines. "The third quarter's growth in portfolio value directly reflects the successful follow-on financing rounds of EdenShield Ltd., Fidmi Medical Ltd., and Vensica Medical Ltd. as well as general commercial and technological progress for other portfolio companies. "

For the third quarter of 2017, total income was US$6.8 million, compared to US$4.1 million in the third quarter of 2016. Total expenses were US$2.7 million in Q3 2017, compared to US$2.4 million in Q3 2016, the result of increased financial expenses is due to the settlement of OCS loan related to exit sale of MitrAssist Medical Ltd. The net profit for Q3 2017 was US$3.0 million, compared with US$1.6 million in Q3 2016.

For the 9 months ended 30 September 2017, the Group reported a gain in the fair value of investments in portfolio companies of $8.3 million, compared to a loss of US$5.0 million in the first 9 months of 2016. Total income in the first 9 months of 2017 was US$13.3 million, compared to total income of US$2.3 million for the same period in 2016. The net profit for the first 9 months was US$3.8 million compared to a net loss of US$3.8 million in the first 9 months of 2016.

Total current assets were US$12.4 million as at 30 September 2017, compared to US$17.3 million as at 31 December 2016. The decline was due to a decrease in short-term investments, which were reduced mainly due to investments in our portfolio companies and operating expenses.

Total non-current assets were US$95.0 million as at 30 September 2017, compared to US$85.3 million as at 31 December 2016. Non-current assets rose as a reflection of the net increase of approximately US$10.3 million in the aggregate fair value of our Portfolio Companies mainly due to the completion of fund raising exercises at favorable terms to the Company, and general commercial or technological progress demonstrated in some Portfolio Companies during the period and the investments in new Portfolio Companies and net of a decrease in the fair market value of various Portfolio Companies and write-offs.

Equity of the Company is US$82.7 million at the end of the third quarter of 2017, compared to US$78.2 million at the end of 2016.

Commenting on corporate developments, Chairman & CEO Steve Rhodes said, "During the third quarter and into the fourth quarter, we have achieved growth at Trendlines on three levels: portfolio valuation, number of portfolio companies, global partnerships, and our shareholder base. In addition to starting four new companies and realizing significant growth in our portfolio value, we expanded our global network of strategic partners to include two new Asian partners. We signed an agreement for a new joint venture company in China in partnership with Shoushan Wealth Holdings to help Trendlines' portfolio companies and other Israeli and Asian medical companies penetrate the medical market in China. We also entered into an MOU with Haier HCH to develop new technologies, solutions and products, deal flow and, investments, as well as to support Trendlines' portfolio companies in China and support Haier HCH's entrepreneurs in Israel."

Mr. Rhodes continued, "The expansion of our shareholder base occurred just following the close of the third quarter with the successful placement of 100 million new shares, raising net proceeds of S$13.34 million. We are pleased with the participation of new institutional, corporate and individual investors, as well as the participation of important existing investors including B. Braun Melsungen AG, the cornerstone investor in Trendlines' November 2015 IPO, which maintained its shareholding in the Company. The net proceeds of the placement will be used for the Group's general working capital and direct and indirect investment in new, prospective and existing portfolio companies."

For full financial information, please see our announcement to the SGX: Unaudited Financial Statement and Dividend Announcement for the Three Months Ended 30 September 2017 (http://investors.trendlines.com/reports-and-presentations/2017).

About The Trendlines Group Ltd.
Trendlines is an innovation investment and commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

Investor Contact Information

Israel:
Judith Kleinman
Director, Investor Relations & Corporate Communications
The Trendlines Group
judith@trendlines.com
Tel: +972.72.260.7000

Singapore:
Reyna MEI Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

-The End-

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg)